Trials / Completed
CompletedNCT05227118
MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 65 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of MK-8189 in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8189 | MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths |
| DRUG | Placebo | MK-8189 matching placebo administered orally QD |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-01-10
- Completion
- 2023-01-10
- First posted
- 2022-02-07
- Last updated
- 2024-09-25
- Results posted
- 2024-09-25
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05227118. Inclusion in this directory is not an endorsement.